Brief: Arbutus Reacquires Greater China Rights to Imdusiran
25/06/2025 12:32
June 25 (Reuters) - Arbutus Biopharma Corp ABUS.O: ARBUTUS REACQUIRES GREATER CHINA RIGHTS TO IMDUSIRAN AND ANNOUNCES SCIENTIFIC ADVISORY BOARD WITH LATE-STAGE CLINICAL FOCUS Source text: ID:nGNX7Whn1 Further company coverage: ABUS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arbutus Biopharma
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Arbutus rises after FDA lifts clinical hold for experimental hepatitis B drug
Brief: Arbutus Announces Final Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
Brief: Arbutus Announces Preliminary Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare